Janine M Preble1, Sukhum Silpa-archa, C Stephen Foster. 1. aMassachusetts Eye Research and Surgery Institution (MERSI) bOcular Immunology and Uveitis Foundation (OIUF), Waltham, Massachusetts, USA cFaculty of Medicine, Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand dHarvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Many patients suffer from the ocular manifestations associated with systemic lupus erythematosus (SLE). Retinal vasculitis and optic neuritis are two of the most vision-threatening complications that can be associated with the disease. Ocular manifestations are often associated with wide-spread systemic inflammation which can be fatal. Thus, immediate recognition and treatment is vital for a positive outcome. RECENT FINDINGS: There is an array of medications available to ophthalmologists for treating the ocular manifestations of SLE. Treating the underlying systemic disease is crucial, as well as treating the active ocular complications. Recently, more attention has been placed on evaluating biologic agents' efficacy in treating the systemic condition. New therapies continue to emerge that have the potential to provide benefit to patients suffering from SLE. SUMMARY: SLE is a serious systemic condition that may first present with ocular manifestations. Thus, it is crucial for ophthalmologists to be equipped with the knowledge to detect and adequately treat the disorder to avoid vision/life-threatening complications. More research is needed to determine which therapy provides the best outcome for patients with limited side-effects.
PURPOSE OF REVIEW: Many patients suffer from the ocular manifestations associated with systemic lupus erythematosus (SLE). Retinal vasculitis and optic neuritis are two of the most vision-threatening complications that can be associated with the disease. Ocular manifestations are often associated with wide-spread systemic inflammation which can be fatal. Thus, immediate recognition and treatment is vital for a positive outcome. RECENT FINDINGS: There is an array of medications available to ophthalmologists for treating the ocular manifestations of SLE. Treating the underlying systemic disease is crucial, as well as treating the active ocular complications. Recently, more attention has been placed on evaluating biologic agents' efficacy in treating the systemic condition. New therapies continue to emerge that have the potential to provide benefit to patients suffering from SLE. SUMMARY:SLE is a serious systemic condition that may first present with ocular manifestations. Thus, it is crucial for ophthalmologists to be equipped with the knowledge to detect and adequately treat the disorder to avoid vision/life-threatening complications. More research is needed to determine which therapy provides the best outcome for patients with limited side-effects.
Authors: Gaurav Seth; K G Chengappa; Durga Prasanna Misra; Ramesh Babu; Pooja Belani; K C Shanoj; Gunjan Kumar; Vir Singh Negi Journal: Rheumatol Int Date: 2018-06-13 Impact factor: 2.631
Authors: Sebastian Boeltz; Melanie Hagen; Jasmin Knopf; Aparna Mahajan; Maximilian Schick; Yi Zhao; Cornelia Erfurt-Berge; Jürgen Rech; Luis E Muñoz; Martin Herrmann Journal: Semin Immunopathol Date: 2019-11-06 Impact factor: 9.623